SUSTAIN OPTIMIZE was a study in people, not animals or cells. It enrolled adults living with type 2 diabetes who were also overweight and were already taking basal insulin at a relatively modest daily amount. The question the researchers asked was practical. If you add a GLP-1 medication and pull back on insulin, how does that compare to simply pushing the insulin dose higher?
The compound involved is semaglutide, given once weekly by subcutaneous injection. Semaglutide is FDA approved for certain uses in type 2 diabetes and weight management, so this is not an investigational peptide in the way some others discussed on this site are. This particular trial tested a specific 2.0 mg once-weekly regimen as an add-on to a reduced dose of insulin glargine.
How the study was set up
The design was a 40-week, phase 3b, open-label, randomised trial. Open-label means participants and researchers knew which treatment each person received, which is worth keeping in mind. A total of 573 participants were randomised in a one-to-one split. One group received semaglutide plus a reduced dose of insulin glargine. The other group kept insulin glargine alone and had its dose titrated upward.
Eligibility required a body mass index of at least 25 and basal insulin use of no more than 40 units per day. The main endpoint was change in HbA1c, a blood marker that reflects average glucose over roughly three months. The trial first tested whether the semaglutide combination was non-inferior, meaning not meaningfully worse, and then whether it was superior.
What the trial reported
On HbA1c, the semaglutide combination met both non-inferiority and superiority. The estimated treatment difference was -0.74 percent, with a 95 percent confidence interval of -0.90 to -0.59. In plain terms, the semaglutide group showed a larger average drop in that blood marker than the insulin-titration group.
The secondary results pointed the same direction. Body weight showed an estimated difference of -8.5 kg favoring the semaglutide combination. Daily insulin dose fell substantially in that group as well. Participant satisfaction, measured with a standardized questionnaire, was reported as higher. Each of these comparisons carried a p-value below 0.0001.
On safety, the abstract reported no new safety concerns. Severe low-blood-sugar events were less frequent in the semaglutide group, with a rate ratio of 0.45. Gastrointestinal events, however, were far more common there: 310 events versus 32 in the insulin-only group. Nausea and related complaints are a familiar feature of GLP-1 medications, and this trial reflected that pattern.
What this does and does not mean
The results describe a group-level comparison over 40 weeks in a selected population. They suggest that, within this trial, adding semaglutide while lowering insulin produced different average outcomes than raising insulin alone. That is what the researchers measured and reported.
It does not mean any individual will see the same numbers. Averages hide wide variation. The higher rate of gastrointestinal events is a real trade-off, not a footnote. And the study says nothing about people who fall outside its entry criteria, such as those on higher insulin doses or without overweight.
One honest limitation
The trial was open-label. Everyone knew who received which treatment. That design can influence subjective measures, and satisfaction scores are exactly the kind of outcome that knowledge of treatment can color. It also does not tell us what happens beyond 40 weeks. Durability, longer-term safety, and outcomes in broader populations are questions this single study cannot answer on its own.
Read alongside other trials, SUSTAIN OPTIMIZE adds one data point to a larger picture. It is a well-sized, randomised comparison with clear endpoints, and it reports both benefits and costs. Weighing those against your own situation is a conversation for your clinician, not a decision to make from an abstract.